Levels of circulating catestatin in different clinical variants of coronary heart disease in patients with chronic heart failure and concomitant type 2 diabetes mellitus and obesity
DOI:
https://doi.org/10.14739/2310-1237.2024.3.309917Keywords:
catestatin, chronic heart failure, type 2 diabetes mellitus, obesity, coronary heart diseaseAbstract
The aim is to assess the levels of circulating catestatin and to establish relationships with various clinical variants of coronary heart disease (CHD) in patients with chronic heart failure (CHF) and concomitant type 2 diabetes mellitus (T2DM) and obesity.
Materials and methods. 154 patients were examined, divided into 4 groups according to the presence of metabolic disorders. Group 1 included patients with CHF with CHD and T2DM and obesity (n = 42). The second group consisted of patients with CHF on the background of CHD with T2DM (n = 46), the third group – with accompanying obesity (n = 36), the fourth group was formed from patients who had signs of heart failure of ischemic origin without metabolic disorders (n = 30). The control group consisted of 30 almost healthy persons of comparable age and sex. In addition, patients were divided into subgroups depending on the clinical form of CHD: stable angina, post-infarction cardiosclerosis (PICS) and diffuse cardiosclerosis.
Results. Comparing the levels of circulating catestatin in groups 1, 2, 3 and 4, significantly lower levels of catestatin were found in patients with stable angina, compared to patients with diffuse cardiosclerosis by 73.25 %, 66.56 %, 69.86 % and 58.22 %, respectively (р ˂ 0.05). Comparison of catestatin levels revealed a decrease in catestatin levels in patients with stable angina compared to patients with PICS by 64.33 %, 63.70 %, 69.25 %, and 52.02 % in groups 1, 2, 3, and 4, respectively (р ˂ 0.05). Comparison of subgroups of diffuse cardiosclerosis and PICS did not reveal significant changes (р ˃ 0.05) in any group of patients. The indicators of catestatin in the control group had significant differences in the form of an increase in the concentration of the peptide, compared to patients with stable angina pectoris, PICS and diffuse cardiosclerosis in all studied groups (р ˂ 0.05). Evaluation of relationships between serum catestatin levels and clinical variants of coronary heart disease demonstrated a stable inverse relationship between catestatin and stable angina pectoris (r = -0.67, p ˂ 0.05) and PICS (r = -0.42, p ˂ 0.05), and with regard to metabolic diseases, a medium-strength inverse relationship with type 2 diabetes was also established (r = -0.54, p ˂ 0.05).
Conclusions. The concentration of catestatin in blood serum had the lowest values in the group of patients with chronic heart failure of ischemic origin with concomitant diabetes mellitus type 2 and obesity, compared to the isolated course of chronic heart failure (p ˂ 0.05), which confirms the anti-inflammatory effects of catestatin and its connection with the insulin resistance progression. Among the clinical variants of coronary heart disease, the lowest levels of catestatin were demonstrated by patients with stable angina pectoris and post-infarction cardiosclerosis (r = -0.67 and r = -0.42, p ˂ 0.05, respectively), which indicates the association of this biomarker with various clinical variants of coronary heart disease.
References
Iyer DR, Venkatraman J, Tanguy E, Vitale N, Mahapatra NR. Chromogranin A and its derived peptides: potential regulators of cholesterol homeostasis. Cell Mol Life Sci. 2023;80(9):271. doi: https://doi.org/10.1007/s00018-023-04908-3
Mahata SK, Corti A. Chromogranin A and its fragments in cardiovascular, immunometabolic, and cancer regulation. Ann N Y Acad Sci. 2019;1455(1):34-58. doi: https://doi.org/10.1111/nyas.14249
McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) With the special contribution of the Heart Failure Association (HFA) of the ESC. Rev Esp Cardiol (Engl Ed). 2022;75(6):523. English, Spanish. doi: https://doi.org/10.1016/j.rec.2022.05.005
Zalewska E, Kmieć P, Sworczak K. Role of Catestatin in the Cardiovascular System and Metabolic Disorders. Front Cardiovasc Med. 2022;9:909480. doi: https://doi.org/10.3389/fcvm.2022.909480
Manolis AA, Manolis TA, Manolis AS. Neurohumoral Activation in Heart Failure. Int J Mol Sci. 2023;24(20):15472. doi: https://doi.org/10.3390/ijms242015472
Watanabe T. The Emerging Roles of Chromogranins and Derived Polypeptides in Atherosclerosis, Diabetes, and Coronary Heart Disease. Int J Mol Sci. 2021;22(11):6118. doi: https://doi.org/10.3390/ijms22116118
Bozic J, Kumric M, Ticinovic Kurir T, Urlic H, Martinovic D, Vilovic M, et al. Catestatin as a Biomarker of Cardiovascular Diseases: A Clinical Perspective. Biomedicines. 2021;9(12):1757. doi: https://doi.org/10.3390/biomedicines9121757
Xue C, Chen K, Gao Z, Bao T, Dong L, Zhao L, et al. Common mechanisms underlying diabetic vascular complications: focus on the interaction of metabolic disorders, immuno-inflammation, and endothelial dysfunction. Cell Commun Signal. 2023;21(1):298. doi: https://doi.org/10.1186/s12964-022-01016-w
Gallo G, Volpe M, Savoia C. Endothelial Dysfunction in Hypertension: Current Concepts and Clinical Implications. Front Med (Lausanne). 2022;8:798958. doi: https://doi.org/10.3389/fmed.2021.798958
Bandyopadhyay GK, Vu CU, Gentile S, Lee H, Biswas N, Chi NW, et al. Catestatin (chromogranin A(352-372)) and novel effects on mobilization of fat from adipose tissue through regulation of adrenergic and leptin signaling. J Biol Chem. 2012 9;287(27):23141-51. doi: https://doi.org/10.1074/jbc.M111.335877
Mir SA, Biswas N, Cheung W, Wan J, Webster N, Macedo E, et al. Chromogranin A pathway: from pathogenic molecule to renal disease. J Hypertens. 2020;38(3):456-66. doi: https://doi.org/10.1097/HJH.0000000000002295
Gao W, Liu JL, Lu X, Yang Q. Epigenetic regulation of energy metabolism in obesity. J Mol Cell Biol. 2021;13(7):480-99. doi: https://doi.org/10.1093/jmcb/mjab043
Mahmoud AM. An Overview of Epigenetics in Obesity: The Role of Lifestyle and Therapeutic Interventions. Int J Mol Sci. 2022;23(3):1341. doi: https://doi.org/10.3390/ijms23031341
Pankova O, Korzh O. Plasma catestatin levels are related to metabolic parameters in patients with essential hypertension and type 2 diabetes mellitus. Heart Vessels. 2024;39(2):144-59. doi: https://doi.org/10.1007/s00380-023-02318-w
Downloads
Additional Files
Published
How to Cite
Issue
Section
License
Authors who publish with this journal agree to the following terms:- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (SeeThe Effect of Open Access).
